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Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients
present good performance status (PS) and are candidate for further treatment. Patients 418 years, PS X50, with metastatic
pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) o12
months received a combination of raltitrexed (3mgm
 2) and oxaliplatin (130mgm
 2) every 3 weeks until progression, toxicity, or a
maximum of six cycles. A total of 41 patients received 137 cycles of chemotherapy. Dose intensity for both drugs was 92% of the
intended dose. Main grade 42 toxicity was: neutropenia in five patients (12%), thrombocytopenia, liver and vomiting in three (7%),
fatigue in two (5%). In total, 10 patients (24%) yielded a partial response, 11 a stable disease. Progression-free survival at 6 months
was 14.6%. Median survival was 5.2 months. Survival was significantly longer in patients with previous PFS 46 months and in patients
without pancreatic localisation. A clinically relevant improvement of quality of life was observed in numerous domains. Raltitrexed–
oxaliplatin regimen may constitute a treatment opportunity in gemcitabine-resistant metastatic pancreatic cancer. Previous PFS
interval may allow the identification of patients who are more likely to benefit from salvage treatment.
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Pancreatic adenocarcinoma has a dismal prognosis due to
early metastatic dissemination even in patients submitted
to surgery with radical intent. As a consequence, effective systemic
treatment has a strategic role in the therapeutic management
of this disease. Unfortunately, very few agents have demonstrated
any activity with reproducible response rates greater than 15%.
While randomised studies have suggested that chemotherapy is
superior to best supportive care in prolonging survival and
improving symptoms in patients with advanced disease (Glimelius
et al, 1996), standard single agent gemcitabine yields a marginal
impact on disease outcome. Median progression-free survival
(PFS) with this agent is approximately 3 months (Burris et al, 1997;
Bramhall et al, 2001, 2002; Berlin et al, 2002; Moore et al, 2003;
Rocha Lima et al, 2004; Van Cutsem et al, 2004; Reni et al, 2005),
and o15% of patients are PF at 6 months (PFS-6) from diagnosis
(Reni et al, 2005). Approximately half of the patients failing
previous treatment present good performance status (PS) and are
willing to undergo further treatment. However, very limited
information concerning the impact of salvage treatment upon
survival and quality of life is available. This patient popula-
tion represents the target for experimental trials aimed at
broadening the chemotherapeutic armamentarium. Raltitrexed
(Tomudex
s AstraZeneca S.p.A., Ben Venue Laboratories Inc.,
Bedford, OH, USA) is a thymidylate synthase inhibitor that is
easily transported in the cell, where it undergoes extensive
polyglutamation within the cells, which extends the intracellular
retention, increases concentration, and ultimately leads to
increased cytotoxicity. Raltitrexed blocks the production of
thymidine monophosphate from deoxyuridine monophosphate
in a reaction-specific manner. Oxaliplatin (Eloxatin
s, Sanofi-
Synthelabo S.p.A, Milan, Italy), a third-generation platinum
analogue, is a diaminocyclohexane platinum that forms interstrand
DNA adducts, which differ from those formed by cisplatin or
carboplatin in their capability to overcome resistance mechanisms.
Preclinical studies suggested that pancreatic cancer cell lines are
highly sensitive towards raltitrexed and oxaliplatin even in
gemcitabine- and 5-fluorouracil-resistant cells (Kornmann et al,
2000; Monti et al, 2004), and that oxaliplatin yields an addictive
antitumour activity when combined with raltitrexed or other
thymidylate synthase inhibitors (Raymond et al, 1998), thus
encouraging the use of these two drugs in experimental protocols
as salvage treatment (Monti et al, 2004). Furthermore, raltitrexed
and oxaliplatin have a noncrossresistant mode of action,
differential toxicity profiles, and can be used in combination as
outpatient therapy in the same doses as for single agent use (Fizazi
et al, 2000).
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sRaltitrexed-oxaliplatin (TOM-OX) combination has been as-
sessed in colorectal cancer and mesothelioma yielding elevated
tumour control rates in 5-fluorouracil or cisplatin pretreated
patients (Cascinu et al, 2002; Seitz et al, 2002). Single agent
raltitrexed obtained 5% partial response (PR) and 29% stable
disease (SD) in 42 patients with pancreatic adenocarcinoma
(Pazdur et al, 1996).
A multicentre phase II trial was undertaken to determine the
activity and safety of TOM-OX combination as salvage treatment
in gemcitabine-resistant metastatic pancreatic cancer.
PATIENTS AND METHODS
Patient population
Patients aged 418 years with histologically or cytologically proven
metastatic pancreatic adenocarcinoma, with at least one bidimen-
sionally measurable target lesion were eligible for this study.
Patients were to have received previous gemcitabine-containing
chemotherapy. No definition of gemcitabine resistance in pan-
creatic cancer exists and no other trial has used this eligibility
criterion. Thus, in the absence of benchmarks to which to refer, it
was arbitrarily decided to include only those patients in whom
progression occurred o12 months from the start of treatment
(i.e. o6 months from treatment conclusion) as it was deemed
unlikely that these patients could achieve relevant benefit with
further gemcitabine administration. Other inclusion criteria were:
Karnofsky PSX50, adequate bone marrow (absolute neutrophil
count (ANC) X1500 cellsmm
 3, platelet count X100000
cellsmm
 3, and haemoglobin X10gdl
 1); kidney function (crea-
tinine clearance X65mlmin
 1) and liver function (serum total
bilirubin p2mgdl
 1, alkaline phosphatase and serum transami-
nases pthree times the upper limit of normal (ULN)). Patients
with prior malignancy were ineligible for the study, with the
exception of those who had had basal-cell carcinoma of the skin,
carcinoma in situ of the cervix, or other cancer for which the
patient had been disease free for at least 5 years. Patients with
ampullary tumours or other histologic variants of pancreatic
carcinoma were ineligible. The study was reviewed and approved
by each local Ethics Committee of the participating institutions
and was conducted in accordance with the Declaration of Helsinki.
All participating patients were required to provide written
informed consent.
Treatment plan
Raltitrexed was diluted in 5% dextrose and given as 15min
intravenous (i.v.) infusion at 3mgm
 2. After a 45min interval,
oxaliplatin was administered in at least 2h i.v. infusion at
130mgm
 2. Patients were systematically given prophylactic
antiemetic treatment with 5-HT3 antagonists. Cycles were repeated
every 3 weeks until PD, unacceptable toxicity, patient’s or
physician’s decision, or a maximum of six cycles. Dose adjust-
ments were made according to the greatest degree of toxicity. In
the case of ANC o1500 cellsmm
 3, of platelet count
o100000cellsmm
 3,o ro fXgrade 3 nonhaematological toxicity,
on the first day of the next cycle, the treatment was withheld until
recovery and then restarted with dose for the drug responsible for
nonhaematological toxicity reduced by 25%. If recovery was not
evident within 2 weeks, the patient was discontinued from the
study. If grade 3 or grade 4 haematological toxicity occurred, doses
for both drugs were reduced by 25% or by 50%, respectively.
Treatment was discontinued in cases of grade 4 haematological
toxicity associated with grade 3 gastro-intestinal toxicity. If grade 2
or grade 3 gastro-intestinal toxicity occurred, raltitrexed dose was
to be reduced by 25% or by 50%, respectively. Treatment was
discontinued in cases of grade 4 gastro-intestinal toxicity. In cases
of decreased creatinine clearance, raltitrexed was administered
every 4 weeks at 75% (55–65mlmin
 1) or 50% (25–54mlmin
 1)
of the original dose. Raltitrexed was discontinued if creatinine
clearance fell below 25mlmin
 1. The oxaliplatin dose was to be
reduced to 100mgm
 2 in cases of paraesthesia or dysesthesia with
pain or functional impairment lasting 47 days, to 80mgm
 2 for
persistent paraesthesia or dysesthesia between two cycles without
functional impairment, or discontinued in cases with persistent
paraesthesia or dysesthesia between two cycles with functional
impairment.
Study evaluations
Pretreatment evaluation consisted of PS assessment, haematologi-
cal and biochemical profiles, CA 19-9 analysis, spiral computed
tomography (CT) scan of the abdomen, and the chest or magnetic
resonance imaging (MRI). During treatment, blood chemistry,
creatinine clearance, and CA 19-9 analysis was performed on day
14, whereas haematological profile was repeated on day 1 of every
cycle. Imaging studies, employing the same method used to
measure the initial target, were repeated every two treatment cycles
to assess objective response. At the end of chemotherapy, CA 19-9
analysis was performed every 40–50 days, and imaging studies
were repeated every 2–3 months, when an increase of CA 19-9 was
observed, or when PD was suspected. The EORTC QLQ-C30
(Aaronson et al, 1993) and PAN26 (Fitzsimmons et al, 1999)
questionnaires for quality of life (QOL) assessment were given to
patients at study entry and every second cycle of chemotherapy,
until PD.
Outcome measures
Side effects were graded according to the Common Toxicity
Criteria defined by the NCI (US), extended by the NCIC (Canada)
version 2.0 (Ajani et al, 1990). The objective tumour response to
treatment was assessed according to the WHO criteria on the basis
of a maximum of three ‘target lesions’ selected before the start of
the treatment. All scans were centrally reviewed by one expert
radiologist. The duration of complete response was defined as the
time between the first documentation of complete disease
resolution and the first documented observation of PD. The
duration of PR was defined as the time between the initiation of
treatment and the time of PD. The PFS was defined as the interval
between the initiation of treatment and the occurrence of PD.
Survival (OS) was measured from the initiation of treatment to the
date of death for any reason or to the last follow-up assessment.
The QOL was assessed using the EORTC QLQ-C30 questionnaire
(Aaronson et al, 1993) supplemented by the pancreatic cancer
module (EORTC QLQ-PAN-26) (Fitzsimmons et al, 1999).
Differences 410 points on the transformed scales were regarded
as clinically significant (Osoba et al, 1998). Mean scale and items
scores were transformed to a 0–100 scale, as described in the
EORTC scoring manual (Fayers et al, 2001). To be assessable for
QOL, patients had to have a baseline QOL assessment and at least
one subsequent QOL assessment. The numbers of patients in each
analysis may differ from scale to scale as some patients may have
had randomly missing scores on certain scales.
Statistical analysis
The primary end point of this trial was to assess the objective
response rate of TOM-OX in gemcitabine-resistant metastatic
pancreatic adenocarcinoma. Secondary end points were PFS, OS,
toxicity, response duration, and QOL. The Simon Minimax two-
stage design was used. The maximum response rate considered of
low interest was 10% and the minimum response rate considered
of interest was 25%. The sample size was calculated with a type I
error of 10% and a test power of 90%. Early discontinuation of the
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sstudy was planned in the case of o3 responses in the first 27
patients. Alternatively, the target enrollment was estimated to be
40 patients. TOM-OX would be considered an active regimen in
this patient population if 46 responses were noted among the 40
enrolled patients. All the statistical analyses were performed on the
intention-to-treat population. The survivor functions curves were
estimated according to the Kaplan–Meier method and compared
using the log-rank test. All the probability values were from two-
sided tests. Analyses were carried out using the Statistica 4.0
statistical package for Windows (1993 Statsoft, Tulsa, OK, USA).
Funding source
Raltitrexed and oxaliplatin were supplied gratuitously by Astra-
Zeneca, Italy and Sanofi-Synthelabo, Italy. No funding sources
supported the work.
RESULTS
Patient population
Between December 2002 and March 2004, 41 patients were entered
into this trial. The characteristics of the patient population are
listed in Table 1. Previous PFS, which was calculated as the interval
between the initiation of latest chemotherapy treatment and the
occurrence of PD, was 1–11.5 months (median 6). With regard to
previous treatment, 16 of 18 patients submitted to surgery with
curative intent received postoperative chemotherapy, which was
followed by radiotherapy in 10 cases, while two patients were
submitted to postoperative chemoradiation and received gemcita-
bine at the time of first recurrence. Two of the 23 patients who did
not receive prior surgery were irradiated. Among 35 patients
receiving a single prior chemotherapy, treatment consisted of
gemcitabine alone in 17 patients, PEFG (cisplatin, epirubicin,
5-fluorouracil, gemcitabine) regimen (Reni et al, 2005) in 16
patients, gemcitabine plus cisplatin or 5-fluorouracil in one case
each. Among six patients receiving either two (n¼5) or three
(n¼1) prior chemotherapy lines, first-line treatment consisted of
gemcitabine in all cases and was followed as second-line treatment
by PEFG regimen (n¼5) or 5-fluorouracil and folinic acid (n¼1);
one patient also received mitomycin-C after gemcitabine and PEFG
regimen, as third-line treatment. In total, 26 patients had PD
during previous chemotherapy, and 15 had an interval o5 months
between the end of previous therapy and PD.
Treatment summary and toxicity
A total of 137 cycles were delivered. Total number of cycles per
patient is reported in Table 2. In all, 13 (32%) patients received six
cycles, while 28 discontinued treatment due to radiologically
confirmed PD (16), clinical PD without radiological assessment
(five), patient or medical decision (five), persistent thrombo-
cytopenia (one), and death of heart failure (one). Dose intensity
was 92% for both drugs. The mean interval between cycles was 22.8
days. The start of a new cycle was delayed by 7–14 days in 18
cycles (13%) due to persistent neutropenia (n¼6) or thrombocy-
topenia (n¼1), fever (n¼1), liver toxicity (n¼2), bowel
subocclusive status (n¼1), delay in CT scan reassessment
(n¼2), patient or medical decision (n¼5). Raltitrexed dose was
reduced in five (12%) patients either by 50% due to G3 vomiting
(n¼1) or by 25% due to grade 2 liver toxicity (n¼1) or fatigue
(n¼3). Oxaliplatin dose was reduced in four (10%) patients by
25% due to G3 liver toxicity (n¼1), G2 liver toxicity, or fatigue
(n¼1 each).
Table 3 summarises the main side effects observed. One patient
died on day 1 of the third cycle due to heart failure. Febrile
neutropenia, or non-neutropenic infections were not observed.
Response and survival
Table 4 summarises the outcome measures. The central radiology
independent review showed 10 PR (24%; 95% confidence interval
Table 1 Patient characteristics at baseline
Characteristic n (%)
Patients enrolled 41
Age (years)
Median 61
Range 25–80
Sex
Male 23 (56)
Female 18 (44)
Karnofsky PS
70–80 16 (39)
90–100 25 (61)
Site of metastases
Liver 33 (80)
Lymphnodes 8 (20)
Lung 12 (29)
Peritoneum 5 (12)
Number of metastatic lesions
1 1 (2)
2–5 24 (59)
45 16 (39)
Prior therapy
Prior pancreatic surgery 18 (44)
Prior radiotherapy 14 (34)
Prior chemotherapy lines
n¼1 35 (85)*
n41 6 (15)
*Gemcitabine alone 17 (49)
*Combination 18 (51)
PS¼performance status; n¼number. *In all, 35 patients received 1 prior
chemotheraphy line. Of those, 17 received Gemcitabine alone and 18 received a
combination chemotherapy.
Table 2 Treatment summary
Number of cycles Number of patients
16
21 8
31
41
52
61 3
Table 3 Treatment-related toxicity per cycle (and worst ever by patient)
Toxicity Grade 0 Grade 1/2 Grade 3 Grade 4 NA
Granulocytes 66 (63) 22 (22) 3 (5) 3 (7) 6 (2)
Platelets 70 (61) 22 (29) 2 (5) 1 (2) 6 (2)
Haemoglobin 39 (29) 54 (66) 1 (2) 0 6 (2)
Stomatitis 98 (93) 2 (7) 0 0 0
Nausea/vomiting 61 (46) 36 (46) 3 (5) 1 (2) 0
Diarrhoea 90 (76) 9 (22) 1 (2) 0 0
Neurologic 81 (68) 19 (32) 0 0 0
Fatigue 72 (49) 27 (46) 2 (5) 0 0
Liver (GOT/GPT) 62 (49) 30 (41) 2 (5) 1 (2) 6 (2)
Liver (GGT/Alk.P) 88 (83) 5 (12) 1 (2) 0 6 (2)
Fever 92 (80) 8 (20) 0 0 0
Kidney 98 (93) 2 (7) 0 0 0
Numbers are expressed as percentages. NA¼not available.
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s(95% CI) 11–37%), 11 SD (27%; 95% CI 13–41%), 15 PD (37%;
95% CI 22–52%), while five patients (12%; 95% CI 2–22%)
discontinued chemotherapy before tumour assessment due to
clinical PD. Median duration of PR was 5.6 months (interquartile
range: 4.3–6.4 months) and five of 10 patients with PR were PF at 6
months. Median duration of SD was 4.0 months (interquartile
range 3.1–4.5 months) and one of 11 patients with SD was PF at 6
months. Of 35 patients, 13 (37%; 95% CI 20–54%) with elevated
CA19.9 basal value had a marker reduction of 450% during
treatment.
All patients, apart from one dying from heart failure while PF,
had PD. In the five patients without radiological documentation of
PD, PFS was calculated as the interval between treatment initiation
and death. Median and 6-month PFS was 1.8 months (interquartile
range: 1.2–4.5 months) and 14.6% (95% CI 4.6–24.6%; Table 4). A
total of 40 patients died. One is alive at 29 months. Median and
1-year OS was 5.2 months (interquartile range: 2.3–7.5 months)
and 12.2% (95% CI 2.2–22.2%; Figure 1; Table 4), respectively.
Median survival for patients with PR, SD, and PD was 7.4, 6.8, and
2.5 months, respectively. Median survival was 2.9 months for 22
patients without CA19.9 reduction and 7.4 months for 13 patients
with CA19.9 reduction 450% (P¼0.006).
Quality of life
At baseline, questionnaires were completed by 29 patients (71%).
Two of those had PD after the first cycle, while three patients
completed only baseline questionnaires. Thus, 24 patients (59%)
were assessable for QOL analysis. In this subset of patients, a
clinically significant improvement in QOL relative to baseline was
observed in health-care satisfaction (50%), body image (42%), fear
for future health (40%), pain (39%), sexuality, digestive symptoms
(33%), QOL 1 and 2 (30–35%), altered bowel habit and cachexia
(30%), cognitive functioning, hepatic symptoms, pancreatic pain
(29%), physical functioning, fatigue (26%), nausea, and appetite
loss (24%).
Exploratory analyses
As the aim of salvage treatment in metastatic pancreatic cancer is
palliative, exploratory analyses of the impact of TOM-OX on OS in
subgroups of patients were performed in an attempt to identify
those who could receive the greatest benefit from treatment
(significance level after multiple comparison adjustment: 0.0036).
Previous chemotherapy including 5-fluorouracil or cisplatin did
not reduce the probability to be PF at 6 months or alive at 12
months after TOM-OX (Table 4). When considering patients who
received only one prior chemotherapy line, no significant
difference in OS was observed among 16 patients previously
treated by PEFG when compared to 17 patients treated by
gemcitabine alone (1-year OS 25.0 vs 0%; P¼0.018). A summary
of univariate and multivariate analyses of the relationship between
OS and patient-, treatment-, and tumour-related variables is
reported in Table 5. Overall survival was significantly longer in
patients with previous PFS ranging between 6.1 and 12 months
relative to those with shorter PFS and in patients without
pancreatic localisation. A trend towards longer OS was observed
in patients submitted to previous surgery. A multivariate analysis
by the Cox proportional hazard model confirmed that previous
PFS and pancreatic localisation were significantly predictive of
survival (Table 5).
DISCUSSION
The present trial showed that TOM-OX regimen was feasible, had
limited toxicity and relevant activity in patients with gemcitabine-
resistant metastatic pancreatic adenocarcinoma, and may consti-
tute a treatment opportunity in this setting. It is noteworthy that
this regimen was also active in patients with 5-fluorouracil- or
cisplatin-resistant disease. Until a decade ago, the use of
chemotherapy in pancreatic cancer was believed to have no role
in the routine treatment of patients with advanced disease
(Lionetto et al, 1995). A few options are currently available for
first-line treatment (Burris et al, 1997; Moore et al, 2005; Reni et al,
2005). However, gemcitabine-based chemotherapy yields a very
limited disease control, and progression usually occurs within a
few months after starting first-line treatment. As no further
standard therapeutic option exists and scarce information on the
impact on outcome of salvage therapy is available, prospective
trials attempting to widen the therapeutic armamentarium against
this disease are warranted. So far, very few studies have
investigated salvage chemotherapy after failure of gemcitabine or
gemcitabine-containing chemotherapy (Stehlin et al, 1999; Oettle
et al, 2000; Ulrich-Pur et al, 2003; Cantore et al, 2004; Milella et al,
Table 4 Activity and efficacy analyses summary
Best response Outcome measures
Previous treatment PR SD PFS-6 OS-12
All patients (n¼41) 10 (24.4%) 11 (26.8%) 6 (14.6%) 5 (12.2%)
PEFG (n¼16) 3 (18.7%) 6 (37.5%) 3 (18.8%) 4 (25.0%)
G( n¼17) 5 (29.4%) 4 (23.5%) 2 (11.8%) 0 (0.0%)
G)PEFG (¼5) 0 (0.0%) 1 (20.0%) 0 (0.0%) 0 (0.0%)
F including
y( n¼23) 5 (21.7%) 7 (30.4%) 4 (17.4%) 5 (21.7%)
n( n¼18) 5 (27.8%) 4 (22.2%) 2 (11.8%) 0 (0.0%)
P including
y( n¼22) 3 (13.6%) 7 (31.8%) 3 (13.6%) 4 (18.2%)
n( n¼19) 7 (36.8%) 4 (21.1%) 3 (15.8%) 1 (5.3%)
n of lines
1( n¼35) 9 (25.7%) 10 (28.6%) 6 (17.1%) 5 (14.3%)
41( n¼6) 1 (16.6%) 1 (16.6%) 0 (0.0%) 0 (0.0%)
n¼number; PR¼partial response; SD¼stable disease; PFS-6¼progression-free at
6 months; OS-12¼alive at 12 months; P¼cisplatin; E¼epirubicin; F¼5-fluorouracil;
G¼gemcitabine; y¼yes; n¼no; )¼followed by.
0
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Figure 1 Overall survival. N¼number of eligible patients. O¼total
number of events at the final analysis. Subsequent numbers are the number
of patients at risk.
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s2004; Reni et al, 2004), one of which was retrospective (Kozuch
et al, 2001). The populations selected were different in terms of
proportion of patients with PS480, which ranged from 0 to 61%,
metastatic patients (73–100%), patients with liver metastases (57–
85%), patients with 41 prior chemotherapy lines (0–29%), and
median PFS after previous treatment (6.0–7.9 months), which was
rarely reported in other series, while in our exploratory analyses it
resulted as an independent factor predicting the outcome of
salvage therapy (Table 6). Furthermore, the sample size of most
series is limited to o20 patients per treatment arm (Oettle et al,
2000; Ulrich-Pur et al, 2003; Milella et al, 2004; Reni et al, 2004),
thus producing data with very large CIs. Given these differences,
Table 5 Exploratory analyses summary
Univariate Multivariate
Variable Subgroups No. of patients 1 year OS (%) P HR 95% CI P
PFS o6 months 22 0.0
X6 months 19 21.1 0.0035 4.27 1.56–11.67 0.007
Surgery Yes 18 22.2
No 23 0.0 0.0049 2.26 0.48–10.79 0.31
CHT lines 1 6 11.4
41 35 0.0 0.1278 1.49 0.38–5.83 0.58
Age p60 19 15.8
460 22 4.5 0.3362 1.27 0.50–3.21 0.62
Gender Male 23 17.4
Female 18 0.0 0.0296 0.52 0.23–1.19 0.13
PS 90–100 25 12.0
70–80 16 6.2 0.2882 1.29 0.49–3.38 0.61
Radiotherapy Yes 14 11.1
No 27 7.1 0.3601 0.78 0.34–1.80 0.56
No. of lesions 2–5 24 4.2
45 16 18.8 0.4529 0.62 0.18–2.12 0.45
Site: liver Yes 33 9.1
No 8 12.5 0.4891 0.96 0.32–2.88 0.94
Site: lung Yes 12 16.7
No 29 6.9 0.4457 1.06 0.31–3.58 0.93
Site: pancreas Yes 26 0.0
No 15 26.7 0.0011 8.46 1.34–53.4 0.03
Site: peritoneum Yes 5 0.0
No 36 11.1 0.3860 0.37 0.08–1.76 0.22
No. of sites 1 7 42.9
41 34 2.9 0.0080 0.70 0.14–3.42 0.66
No.¼number; CHT¼chemotherapy; PFS¼progression-free survival; OS¼overall survival; PS¼performance status; HR¼hazard ratio; CI¼confidence interval.
Table 6 Results of salvage therapy for pancreatic adenocarcinoma
Ref No. of pts Treatment m. age PS 0 M (%) liver M (%) 41CHT (%) PPFS ORR (%) mPFS PFS-6 (%) 1 year OS (%)
7 30 I+E 60 30 100 60 23 Nr 10 4.1 Nr 23
15
a 34 G-FLIP 64 Nr 100 85 29 Nr 24 3.9 20 20
17 17 F+celecoxib 60 35 82 Nr 0 Nr 35 1.9 6 20
21 18 T 59 Nr 100 Nr 22 7.9 5.5 3.3 Nr Nr
26 15 MDI 61 26 100 60 20 Nr 0 1.7 0 0
29 33 Ru 62 0 73 57 Nr Nr 9 Nr Nr 6
30 19 R 60 21 100 74 0 Nr 0 2.5 Nr 0
30 19 R+I 63 21 100 63 0 Nr 16 4.0 Nr 22
cs 41 R+E 61 61 100 80 15 6.0 24 1.8 15 12
Ref¼reference; No. of pts¼number of patients; m. age¼median age; PS 0¼performance status¼0 (ECOG) or 90–100 (Karnofsky); M¼metastatic; CHT¼% of patients
with 41 previous chemotherapy lines; PPFS¼previous progression-free survival; ORR¼objective response rate; m PFS¼median progression-free survival; PFS-
6¼progression-free survival at 6 months; 1 year OS¼overall survival at 1 year; cs¼current series; I¼irinotecan; E¼eloxatin; G¼gemcitabine; F¼5-fluorouracil;
L¼leucovorin; P¼cisplatin; T¼paclitaxel; M¼mitomycin; D¼docetaxel; Ru¼rubitecan; R¼raltitrexed; Nr¼not reported.
aRetrospective.
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sthe lack of information on important prognostic factors, and other
potential bias related to phase II trial design, results are difficult to
compare across trials, especially in terms of survival. Activity
observed in the current trial (PR: 24%) was consistent with the
response rate of 16–35% previously reported with other active
regimens (Kozuch et al, 2001; Ulrich-Pur et al, 2003; Milella et al,
2004) and compares favourably with the 0–10% objective
responses reported elsewhere (Stehlin et al, 1999; Oettle et al,
2000; Ulrich-Pur et al, 2003; Cantore et al, 2004; Reni et al, 2004).
The median PFS of 1.8 months observed with TOM-OX regimen
was slightly shorter than the median PFS of 1.7–4.1 months
reported in other series (Stehlin et al, 1999; Oettle et al, 2000;
Kozuch et al, 2001; Ulrich-Pur et al, 2003; Cantore et al, 2004;
Milella et al, 2004; Reni et al, 2004). However, it is likely that this
depended on the timing of radiographic assessment, which was
performed more frequently in the current trial and was therefore
more prone to intercept early PD. Consistently, PFS-6 was identical
in our series and in the retrospective series which had previously
obtained the longest median PFS among published series (Kozuch
et al, 2001). With regard to grade 3–4 toxicity, neutropenia (12%),
nausea/vomiting (7%), and liver enzymes increase (7%) observed
in our series were within the range reported with other regimens
(5–38, 3–14, and 5–13%, respectively). Fatigue (5%) was reported
in a single series (10% (Reni et al 2004)). Diarrhoea (2%) was
observed less often relative to other series (3–10%). Of note, less
toxicity was observed in our series relative to TOM-OX when
administered to patients with metastatic colorectal cancer (Cascinu
et al, 2002; Seitz et al, 2002), namely, 17–33% liver toxicity, 10–
30% neutropenia, 5–13% nausea-vomiting, 11–16% fatigue, and
7–17% diarrhoea were reported in metastatic colorectal cancer
(Cascinu et al, 2002; Seitz et al, 2002). The differences in toxicity
may reflect different selection of patients (e.g. in terms of PS) and
may suggest that toxicity profile could be different in different
tumour sites. As the aim of salvage therapy in patients with
metastatic pancreatic cancer is purely palliative, some concern
could be raised that the improvement in clinical outcome is not
achieved at the cost of impaired QOL. Clinical benefit response was
proposed to address this issue (Burris et al, 1997). However, this
measure was not validated and has been criticised for using
selected variables that do not reflect QOL (Hoffman and Glimelius,
1998). Thus, we preferred a more reliable and validated measure,
such as the EORTC QLQ questionnaire. No data to which to
compare the present findings are available in the literature.
Raltitrexed–oxaliplatin regimen yielded a clinically significant
improvement relative to baseline in a large proportion of patients
in several QOL domains, including most of the important
symptoms that are frequently associated with pancreatic cancer.
Altogether, a median overall survival of 3.5–10 months and
median PFS of 2–4 months was achieved with active salvage
therapy. It is of note that 12–23% patients with metastatic disease
are alive at 1 year from salvage treatment start (current series,
Kozuch et al, 2001; Ulrich-Pur et al, 2003; Cantore et al, 2004;
Milella et al, 2004). These figures are similar to those observed
after gemcitabine in the first-line setting. While a bias in favour of
salvage therapy due to better selection of patients cannot be ruled
out, these data suggest that an appropriately selected subset of
patients, for example, on the basis of previous PFS, with
gemcitabine-refractory disease may yield a relevant clinical and
survival benefit from further treatment. This hypothesis should be
tested in a phase III trial against best supportive care.
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